In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Shivaprakash, M R ^a   Geertsen, Erik ^b   Chakrabarti, Arunaloke ^a   Mouton, Johan W ^b,c   Meis, Jacques F ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anidulafungin; Aspergillus flavus; Caspofungin; Epidemiological cut off; Micafungin; Posaconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FLAVUS; BROTH DILUTION; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; EPSILOMETER TEST; FUNGAL ENDOPHTHALMITIS; FUNGAL SINUSITIS; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; INDIA; KERATOMYCOSIS; MINIMUM INHIBITORY CONCENTRATION; NETHERLANDS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ENVIRONMENTAL MICROBIOLOGY; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; NETHERLANDS; NITRILES; PYRIDINES; TRIAZOLES;

ASPERGILLUS; ASPERGILLUS FLAVUS; FUNGI;

EID: 80052794427     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01996.x     Document Type: Article

References (36)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
2. Balajee SA, Kano R, Baddley JW et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3138-41.
3. Morgan J, Wannemuehler KA, Hadley S et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(Suppl. 1): 49-58.
4. Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol 2009; 47(Suppl. 1): 261-70.
5. Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007; 153: 1677-92.
6. Ford S, Friedman L. Experimental study of the pathogenicity of aspergilli for mice. J Bacteriol 1967; 94: 928-33.
7. Hsueh PR, Lau YJ, Chuang YC et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan Program Data from 2003. Antimicrob Agents Chemother 2005; 49: 512-7.
8. Odds FC, Gerven FV, Espinel-Ingroff A et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42: 282-8.
9. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2003; 47: 3085-8.
10. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-76.
11. Klaassen CHW, de Valk HA, Curfs-Breuker IM, Meis JF. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J Antimicrob Chemother 2010; 65: 901-5.
12. Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL 4815), voriconazole, and fluconazole against 1, 007 isolates of Zygomycetes, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52: 1396-1400.
13. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61(Suppl. 1): 19-30.
14. Martín de la Escalera C, Aller AI, Lopez-Oviedo E et al. Activity of BAL 4815 against filamentous fungi. J Antimicrob Chemother 2008; 61: 1083-6.
15. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006; 57: 135-8.
16. De Hoog GS, Guarro J, Gene J et al. Atlas of Clinical Fungi. Utrecht, The Netherlands: Centraalbureau voor Schimmelcultures, 2000.
17. De Valk HA, Meis JF, de Pauw BE, Donnelly JP, Klaassen CH. Comparison of two highly discriminatory molecular fingerprinting assays for analysis of multiple Aspergillus fumigatus isolates from patients with invasive aspergillosis. J Clin Microbiol 2007; 45: 1415-9.
18. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi - Second edition: Approved Standard M38-A2. CLSI, Wayne, PA, USA, 2008.
19. White RL, Kays MB, Friedrich LV, Del Bene VE. Impact of different statistical methodologies on the evaluation of the in vitro MICs for Bacteroides fragilis of selected cephalosporins and cephamycins. J Antimicrob Chemother 1993; 31: 57-64.
20. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52: 2468-72.
21. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15.
22. Seo K, Akiyoshi H, Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol Immunol 1999; 43: 1017-25.
23. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother 2009; 53: 2192-5.
24. Diekema DJ, Messer A, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-6.
25. Alcazar-Fuoli L, Rodriguez-Tudela JL, Mellado E. Antifungal drug resistance in molds: clinical and microbiological factors. Curr Fungal Infect Rep 2008; 2: 36-42.
26. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 2009; 47: 3323-5.
27. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion E-test procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003; 41: 403-9.
28. Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303, 366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998; 42: 2726-30.
29. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-71.
30. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
31. Perkhofer S, Lechner V, Lass-Flörl C. In vitro activity of isavuconazole against Aspergillus species and Zygomycetes according to the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009; 53: 1645-7.
32. Pfaller MA, Messer SA, Boyken L et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46: 2568-72.
33. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-8.
34. Baddley JW, Marr KA, Andes DR et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3271-5.
35. Lionakis MS, Lewis RL, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005; 52: 15-20.
36. Verweij PE, Howard SJ, Melchers WJG, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Res Updates 2009; 12: 141-7.